149 related articles for article (PubMed ID: 21045706)
1. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: who are the high-risk patients and what are the best treatment options?
Robert G; Descazeaud A; de la Taille A
Curr Opin Urol; 2011 Jan; 21(1):42-8. PubMed ID: 21045706
[TBL] [Abstract][Full Text] [Related]
2. An algorithm for medical management in male lower urinary tract symptoms.
Djavan B; Margreiter M; Dianat SS
Curr Opin Urol; 2011 Jan; 21(1):5-12. PubMed ID: 21045704
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology for common urologic diseases: 2011 review for the primary care physician.
Liu XS; Folia C; Gomella LG
Can J Urol; 2011 Apr; 18 Suppl():24-38. PubMed ID: 21501548
[TBL] [Abstract][Full Text] [Related]
4. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Lowe FC
Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
[TBL] [Abstract][Full Text] [Related]
5. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
Trachtenberg J
BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
[TBL] [Abstract][Full Text] [Related]
6. Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile.
Crawford ED
BJU Int; 2005 Jun; 95 Suppl 4():1-5. PubMed ID: 15871729
[No Abstract] [Full Text] [Related]
7. Switch from phytotherapy to tamsulosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
Gross AJ; Busse M; Leonard J; Schumacher H
Prostate Cancer Prostatic Dis; 2005; 8(3):210-4. PubMed ID: 15883586
[TBL] [Abstract][Full Text] [Related]
8. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms.
Sarma AV; Wei JT
N Engl J Med; 2012 Jul; 367(3):248-57. PubMed ID: 22808960
[No Abstract] [Full Text] [Related]
9. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
11. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines.
Cornu JN; Cussenot O; Haab F; Lukacs B
Eur Urol; 2010 Sep; 58(3):450-6. PubMed ID: 20554374
[TBL] [Abstract][Full Text] [Related]
12. Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms.
Parsons JK
Curr Opin Urol; 2011 Jan; 21(1):1-4. PubMed ID: 21045705
[TBL] [Abstract][Full Text] [Related]
13. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system.
Barendrecht MM; Koopmans RP; de la Rosette JJ; Michel MC
BJU Int; 2005 Jun; 95 Suppl 4():19-28. PubMed ID: 15871732
[No Abstract] [Full Text] [Related]
14. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
Chapple CR
BJU Int; 2004 Sep; 94(5):738-44. PubMed ID: 15329091
[TBL] [Abstract][Full Text] [Related]
15. Change in International Prostate Symptom storage subscore after long-term medical therapy in BPH patients: finasteride and alpha-blocker combination therapy in men with moderate-to-severe LUTS/BPH in Korea.
Lee JY; Lee SH; Kim SJ; Kim CS; Lee HM; Kim CI; Chung BH
Urology; 2011 Jan; 77(1):171-6. PubMed ID: 20691464
[TBL] [Abstract][Full Text] [Related]
16. Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise.
Speakman M; Batista J; Berges R; Chartier-Kastler E; Conti G; Desgrandchamps F; Dreikorn K; Lowe F; O'Leary M; Perez M; Trachtenberg J; Tubaro A; Meesen B; Smets L; Stoevelaar H
Prostate Cancer Prostatic Dis; 2005; 8(4):369-74. PubMed ID: 16130013
[TBL] [Abstract][Full Text] [Related]
17. [Medical therapy of benign prostatic hyperplasia].
Altarac S
Lijec Vjesn; 2005; 127(11-12):316-23. PubMed ID: 16583940
[TBL] [Abstract][Full Text] [Related]
18. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
Miner M; Rosenberg MT; Perelman MA
Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
[TBL] [Abstract][Full Text] [Related]
19. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
20. Medical treatment for benign prostatic hyperplasia: Where do we stand?
Rossanese M; Crestani A; Inferrera A; Giannarini G; Bartoletti R; Tubaro A; Ficarra V
Urologia; 2019 Aug; 86(3):115-121. PubMed ID: 31282310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
